Kymera Therapeutics Inc

+0.65 (+1.15%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)2.92B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$19.91 Million
Adjusted EPS-$0.37
See more estimates
10-Day MA$56.09
50-Day MA$59.13
200-Day MA$53.38
See more pivots

Kymera Therapeutics Inc Stock, NASDAQ:KYMR

200 Arsenal Yards Boulevard, Suite 230, Watertown, Massachusetts 02472
United States of America
Phone: +1.857.285.5300
Number of Employees: 75


Kymera Therapeutics, Inc. operates as a biotechnology company, which engages in curing untreatable diseases. It focuses on discovering and developing novel small molecule therapeutics. The firm's proprietary integrated degradation platform consists of informatics-driven target identification, novel E3 ligases and ligands, proprietary predictive modeling, and novel degradation tools. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.